We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.71 | -1.41% | 49.50 | 49.20 | 51.16 | 49.835 | 49.08 | 49.09 | 2,757,468 | 01:00:00 |
From May 2019 to May 2024
By William Horobin
PARIS--French drug company Sanofi SA said Wednesday its candidate for a dengue vaccine was effective in 60.8% of cases in a Phase 3 study in Latin America.
Sanofi said the study of 20,875 children and adolescents in the region also showed the trial vaccine was effective against each of the four serotypes of dengue, a disease transmitted by mosquitoes that threatens nearly half the world's population.
"For the first time ever, after 20 years of research and industrial commitment, dengue is set to become a vaccine-preventable disease," said Olivier Charmeil, chief executive of Sanofi Pasteur, the vaccines division of Sanofi.
Sanofi said there was also a 80.3% reduction in the risk of hospitalization due to dengue during the study.
The drug maker, which has conducted similar trials in Asia, said data from studies involving more than 40,000 people in 15 countries will be submitted to health authorities in countries where dengue is a priority.
Write to William Horobin at william.horobin@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
